The application of carbon nanoparticles in D2 gastrectomy and lymph nodes harvesting for early gastric cancer

Prospective, randomize-controlled study on the application of carbon nanoparticles in D2 gastrectomy and lymph nodes harvesting for early gastric cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IIR-17011197

Enrollment

Unknown

Registered

2017-04-20

Start date

2017-05-01

Completion date

Unknown

Last updated

2017-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Standard:D2 Lymphadenectomy

CNP:CNP Injection+D2 Lymphadenectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Gastric cancer diagnosed by gastroscopy and biopsy; 2) Staging diagnosis is complete by means of enhanced CT scan and/or endoscopic ultrasonography (EUS); 3) Clinical staging is cT1NOM0 cT1N1M0 or cT2NOM0; 4) ECOG less than 2 points, tolerant for gastrectomy and D2 lymph node dissection; 5) Be able to follow the study instructions and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) Remnant gastric cancer, recurrent gastric cancer and abdominopelvic multiple primary cancer; 2) D2 lymph node dissection is not performed; 3) Metastatic gastric cancer is confirmed by intraoperative exploration; 4) Non gastric cancer is confirmed by postoperative pathological examination; 5) The sampling or report of lymph nodes does not conform to the standards in this study.

Design outcomes

Primary

Measure	Time frame
Total number of lymph nodes;	—

Secondary

Measure	Time frame
Total number of stained lymph nodes;	—

Countries

China

Contacts

Public ContactQun Zhao

Hebei Medical University affiliated Fourth Hospital

zhaoqun516@126.com+86 13930162111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026